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RESEARCH
InforMing the PAthway of COPD Treatment 
(IMPACT) trial: fibrinogen levels predict risk 
of moderate or severe exacerbations
Dave Singh1, Gerard J. Criner2, Mark T. Dransfield3, David M. G. Halpin4, MeiLan K. Han5, Peter Lange6, 
Sally Lettis7, David A. Lipson8,9, David Mannino10, Neil Martin11,12, Fernando J. Martinez13, Bruce E. Miller8, 
Robert Wise14, Chang‑Qing Zhu7 and David Lomas15* 
Abstract 
Background: Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with 
chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/
vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients with symptomatic COPD at risk of exacer‑
bations. This analysis used IMPACT trial data to examine the relationship between fibrinogen levels and exacerbation 
outcomes in patients with COPD.
Methods: 8094 patients with a fibrinogen assessment at Week 16 were included, baseline fibrinogen data were not 
measured. Post hoc analyses were performed by fibrinogen quartiles and by 3.5 g/L threshold. Endpoints included 
on‑treatment exacerbations and adverse events of special interest (AESIs).
Results: Rates of moderate, moderate/severe, and severe exacerbations were higher in the highest versus lowest 
fibrinogen quartile (0.75, 0.92 and 0.15 vs 0.67, 0.79 and 0.10, respectively). The rate ratios (95% confidence interval 
[CI]) for exacerbations in patients with fibrinogen levels ≥ 3.5 g/L versus those with fibrinogen levels < 3.5 g/L were 
1.03 (0.95, 1.11) for moderate exacerbations, 1.08 (1.00, 1.15) for moderate/severe exacerbations, and 1.30 (1.10, 1.54) 
for severe exacerbations. There was an increased risk of moderate/severe exacerbation (hazard ratio [95% CI]: highest 
vs lowest quartile 1.16 [1.04, 1.228]; ≥ 3.5 g/L vs < 3.5 g/L: 1.09 [1.00, 1.16]) and severe exacerbation (1.35 [1.09, 1.69]; 
1.27 [1.08, 1.47], respectively) with increasing fibrinogen level. Cardiovascular AESIs were highest in patients in the 
highest fibrinogen quartile.
Conclusions: Rate and risk of exacerbations was higher in patients with higher fibrinogen levels. This supports the 
validity of fibrinogen as a predictive biomarker for COPD exacerbations, and highlights the potential use of fibrinogen 
as an enrichment strategy in trials examining exacerbation outcomes.
Trial registration: NCT02164513
Keywords: Fibrinogen, COPD exacerbations, Pharmacotherapy, COPD
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Background
Chronic obstructive pulmonary disease (COPD), a com-
mon disease characterized by persistent respiratory 
symptoms and airflow limitation, is associated with a 
substantial economic and social burden and was the 
third leading cause of death in 2017 worldwide [1, 2]. The 
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InforMing the PAthway of COPD Treatment (IMPACT) 
study compared once-daily single-inhaler triple therapy 
with fluticasone furoate, umeclidinium and vilanterol 
(FF/UMEC/VI) with the dual therapies FF/VI and 
UMEC/VI in patients with symptomatic COPD at risk of 
exacerbations. This study demonstrated that FF/UMEC/
VI resulted in a significantly lower annual rate of mod-
erate/severe COPD exacerbations and greater improve-
ments in both lung function and health-related quality of 
life compared with either dual therapy [3].
Forced expiratory volume in 1 s  (FEV1) is a widely used 
lung function marker of COPD disease severity, but cor-
relates poorly with symptoms and does not reflect lev-
els of disease activity [2, 4–6]. Patients with more active 
COPD disease are more likely to experience faster dis-
ease progression; for example, patients with more exac-
erbations experience a faster decline in lung function [7, 
8]. Therefore, alternative and more sensitive biomark-
ers are needed that are reflective of disease activity, and 
may predict future risk of events such as exacerbations. 
Fibrinogen is an acute phase soluble plasma glycopro-
tein that is primarily synthesized in the liver and is con-
verted into fibrin by thrombin during blood coagulation 
[4]. Plasma fibrinogen was qualified by the US Food and 
Drug Administration (FDA) in 2015 as the first prognos-
tic or enrichment biomarker for exacerbations and/or 
all-cause mortality (ACM) in patients with COPD [9, 10]. 
This validation was based on an analysis of an integrated 
study database, which demonstrated that high baseline 
fibrinogen levels in individuals with COPD were associ-
ated with an increased risk of exacerbations requiring 
hospitalization within 12  months and an increased risk 
of death within 36 months [11, 12]. Previous research on 
a subset of the ECLIPSE cohort indicated that fibrino-
gen was the most stable of 34 biomarkers assessed over a 
period of 3 months, a critical feature for clinically useful 
biomarkers [4, 13]. Additionally, fibrinogen is routinely 
measured in clinical practice, and therefore appears to be 
a practical blood biomarker for systemic inflammation 
in COPD [4]. A fibrinogen level of 3.5 g/L has been pro-
posed as a threshold for identifying patients at increased 
risk of exacerbations requiring hospitalization and ACM 
[11].
This analysis used data collected in the IMPACT trial 
to provide further information regarding the associa-




The IMPACT trial (study CTT116855, NCT02164513) 
was a Phase III, randomized, double-blind, parallel-
group, multicenter study conducted in 37 countries 
between June 2014 and July 2017. The study design has 
been described in detail previously [3]. Briefly, the total 
study duration was approximately 55 weeks, consisting of 
a 2-week run-in period, 52-week treatment period, and a 
1-week safety follow-up period. Study patients were ran-
domized (2:2:1) to receive triple therapy with FF/UMEC/
VI 100/62.5/25 µg, or dual therapy with FF/VI 100/25 µg 
or UMEC/VI 62.5/25  µg administered once daily via 
the Ellipta dry powder inhaler. Patients continued use 
of their existing COPD medications during the run-in 
period and were provided with albuterol for use on an as-
needed basis (rescue medication) throughout the study. 
All patients provided written informed consent. The 
study was conducted in accordance with Good Clinical 
Practice guidelines and the provisions of the Declaration 
of Helsinki and received approval from local institutional 
review boards or independent ethics committees.
Inclusion/exclusion criteria have been described previ-
ously [3, 14]. Eligible patients were ≥ 40 years of age, with 
symptomatic COPD (COPD Assessment Test score ≥ 10) 
and either a post-bronchodilator  FEV1 < 50% of the pre-
dicted normal value and a history of ≥ 1 moderate or 
severe exacerbation in the previous year, or a post-bron-
chodilator  FEV1 of > 50 to < 80% of the predicted normal 
value and ≥ 2 moderate exacerbations or ≥ 1 severe exac-
erbation in the previous year.
The intent-to-treat (ITT) population comprised all 
randomized patients, excluding those randomized in 
error [14]. The fibrinogen population is a subset of the 
ITT population that included patients with a fibrinogen 
assessment at Week 16, fibrinogen data were not col-
lected prior to Week 16. Previous work has shown that 
treatment with oral steroids or inhaled corticosteroid/
long-acting β2-agonist (ICS/LABA) did not have an effect 
on fibrinogen levels [15, 16].
Annual rate of COPD exacerbations and ACM were 
analyzed post hoc in the fibrinogen population according 
to a fibrinogen threshold: ≥ or < 3.5  g/L and by fibrino-
gen quartiles (Quartile 1: < 2.780 g/L; Quartile 2: ≥ 2.780 
to < 3.280 g/L; Quartile 3: ≥ 3.280 to < 3.830 g/L; Quartile 
4: ≥ 3.830  g/L). Analysis of safety was carried out using 
fibrinogen quartiles.
Study endpoints
Study endpoints have been described previously, with 
the primary endpoint from the IMPACT trial being the 
annual rate of moderate/severe exacerbations during 
treatment [3, 14]. This analysis assessed the following 
endpoints from Week 16: on-treatment exacerbations 
(moderate, moderate/severe, severe), on- and off-treat-
ment ACM and on-treatment adverse events of special 
interest (AESIs). A moderate exacerbation was defined 
as an exacerbation leading to treatment with antibiotics 
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or systemic corticosteroids. A severe exacerbation was 
one resulting in hospitalization or death. On-/off-treat-
ment deaths were defined as those that occurred after 
Week 16 and study treatment stop date and projected 
Week 52 date (based on treatment start date) plus 7 days 
(inclusive).
This analysis evaluated the association between fibrino-
gen levels at Week 16 and exacerbations, mortality and 
AESIs, in particular cardiovascular (CV) events and 
pneumonia. To confirm that Week 16 fibrinogen could 
be used as a baseline value for exacerbation analyses, 
we assessed the magnitude of the difference in Week 
16 fibrinogen between the treatment groups to check 
whether fibrinogen levels were affected by treatment. 
Furthermore, to assess whether the Week 16 fibrinogen 
population was generalizable to all patients we evaluated 
exacerbation history between the patients who withdrew 
at Week 16 versus those who remained in the study.
Statistical analyses
These post hoc analyses were performed in two stages. 
First, baseline characteristics were summarized in the 
fibrinogen population using screening and baseline visit 
data. Analysis of variance (ANOVA) was used to assess 
the magnitude of differences in fibrinogen levels at Week 
16 between treatment groups. The Scheffe multiple com-
parison procedure was used to compare the difference 
between treatment groups. The second stage includes all 
other analyses. Fibrinogen data collected at Week 16 was 
considered as baseline in this post hoc analysis. All analy-
ses were performed using endpoint data from Week 16 
onwards. For example, only exacerbations that occurred 
after Week 16 were considered as an event in the analy-
sis of COPD exacerbations annual rate and the analysis of 
time-to-first COPD exacerbation.
The rate of on-treatment COPD exacerbations (mod-
erate/severe, moderate, severe) was analyzed using a 
generalized linear model assuming a negative binomial 
distribution. Rate of on-treatment COPD exacerbation 
analyses were performed by comparing fibrinogen sub-
groups (fibrinogen threshold [3.5  g/L] and fibrinogen 
quartiles) with combined treatment groups and by com-
paring treatment groups for each fibrinogen subgroup 
(fibrinogen threshold [3.5 g/L] and fibrinogen quartiles). 
The time-to-first on-treatment COPD exacerbation 
(moderate, moderate/severe, severe) was analyzed using 
a Cox proportional hazards model by comparing fibrin-
ogen subgroups with combined treatment groups. The 
relationship between exacerbation rate and fibrinogen 
was also explored by using fractional polynomials mod-
elling, in which fibrinogen was included as a continuous 
variable in the model. The analyses of exacerbation rates 
comparing fibrinogen subgroups included covariates of 
treatment group, gender, exacerbation history in the past 
12 months (≤ 1, ≥ 2 moderate/severe), smoking status (at 
screening), geographical region and post-bronchodilator 
percent predicted forced expiratory volume in 1 s (FEV1; 
at screening) and fibrinogen quartile group or 3.5  g/L 
threshold as applicable. The fibrinogen subgroup analy-
ses of exacerbation rates comparing treatment groups 
included covariates of treatment group, gender, exac-
erbation history in the past 12  months (≤ 1, ≥ 2 moder-
ate/severe), smoking status (at screening), geographical 
region and post-bronchodilator percent predicted FEV1 
(at screening). Patients were only included in the model 
if they had at least 1 day at risk of an on-treatment exac-
erbation from Week 16. The time at risk excluded any 
days after Week 16 when a patient was experiencing an 
exacerbation that started on or prior to Week 16. Analy-
sis by continuous fibrinogen level was performed using 
fractional polynomials and included covariates of treat-
ment group, gender, exacerbation history (≤ 1, ≥ 2 mod-
erate/severe), smoking status (at screening), geographical 
region, post-bronchodilator percent predicted  FEV1 (at 
screening), FP1, FP2, interaction terms for FP1 by treat-
ment, FP2 by treatment, and with logarithm of time on-
treatment post Week 16 as an offset variable. FP1 and 
FP2 represent continuous transformations of fibrinogen 
at Week 16. Subgroup models by fibrinogen quartile 
at Week 16 with the same covariates but excluding FP 
terms are overlaid on the plots at the subgroup median 
fibrinogen value. Time to on- and off- treatment ACM 
was analyzed by calculation of Kaplan–Meier probability 
estimates for each fibrinogen subgroup. Adverse events 
(AEs), serious adverse events (SAEs) and AESIs were 
summarized using descriptive statistics.
Results
Of the 10,355 patients enrolled in the IMPACT study, 
8094 had Week 16 fibrinogen data available and were 
included in this analysis (Table  1). Demographics and 
baseline characteristics were generally similar across 
Week 16 fibrinogen quartile or 3.5  g/L threshold sub-
groups and consistent with the ITT population (Table 1). 
Baseline characteristics by fibrinogen subgroup and 
treatment arms are presented in Table  1 in Additional 
File 1 (quartiles) and Table 2 in Additional File 1 (3.5 g/L 
threshold). The median (interquartile range [IQR]) over-
all (all treatment combined) fibrinogen level at Week 16 
was 3.280 (2.780–3.830) g/L.
Week 16 and baseline comparison
Exacerbation history in the 12  months prior to screen-
ing was similar between patients who withdrew before 
Week 16 and those who remained in the study (Table 3 
in Additional File 1). Table  2 summarizes exacerbations 
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Table 1 Baseline characteristics and demographics by fibrinogen subgroup at Week 16
Quartile 1, fibrinogen value < 25th percentile; Quartile 2, fibrinogen value > 25th percentile and < median; Quartile 3, fibrinogen value ≥ median and < 75th percentile; 
Quartile 4, fibrinogen value ≥ 75th percentile
BMI body mass index, SD standard deviation
a Fibrinogen level descriptor (g/L)
b Risk factors includes past and current events
























Age, years, mean 
(SD)
65.2 (8.4) 65.0 (8.3) 65.2 (8.2) 65.5 (8.1) 65.2 (8.3) 65.3 (8.1) 65.2 (8.2) 65.3 (8.27)
Male, n (%) 1516 (75) 1345 (66) 1269 (63) 1356 (66) 3503 (69) 1983 (65) 5846 (68) 6870 (66)
BMI, kg/m2, mean 
(SD)
25.4 (5.3) 26.3 (5.8) 27.2 (6.2) 27.6 (6.6) 26.1 (5.6) 27.6 (6.6) 26.6 (6.1) 26.6 (6.1)
Smoking status, 
n (%)
 Current 554 (27) 676 (33) 787 (39) 785 (38) 1614 (32) 1188 (39) 2802 (35) 3587 (35)




  FEV1 (L), mean 
(SD)
1.348 (0.4929) 1.315 (0.4923) 1.275 (0.4833) 1.241 (0.4652) 1.320 (0.4914) 1.251 (0.4716) 1.294 (0.4851) 1.272 (0.4860)
  FEV1% predicted, 
mean (SD)
48.0 (14.9) 46.8 (14.6) 45.7 (14.8) 44.4 (14.3) 47.1 (14.8) 44.7 (14.5) 46.2 (14.7) 45.5 (14.8)
  FEV1/FVC ratio, 
mean (SD)
0.472 (0.1185) 0.475 (0.1187) 0.474 (0.1193) 0.473 (0.1192) 0.473 (0.1182) 0.475 (0.1201) 0.474 (0.1189) 0.470 (0.1196)
COPD exacerba‑
tions in previous 
year, n (%)
 Moderate
  0 367 (18) 370 (18) 354 (18) 397 (19) 916 (18) 572 (19) 1488 (18) 1936 (19)
  1 636 (32) 701 (35) 705 (35) 696 (34) 1681 (33) 1057 (35) 2738 (34) 3542 (34)
   ≥ 2 1014 (50) 954 (47) 943 (47) 957 (47) 2448 (49) 1420 (47) 3868 (48) 4877 (47)
 Moderate/severe
  0 3 (< 1) 1 (< 1) 1 (< 1) 1 (< 1) 5 (< 1) 1 (< 1) 6 (< 1) 9 (< 1)
  1 883 (44) 909 (45) 912 (46) 925 (45) 2247 (45) 1382 (45) 3629 (45) 4691 (45)
   ≥ 2 1131 (56) 1115 (55) 1089 (54) 1124 (55) 2793 (55) 1666 (55) 4459 (55) 5655 (55)
 Severe
  0 1532 (76) 1507 (74) 1500 (75) 1501 (73) 3796 (75) 2244 (74) 6040 (75) 7684 (74)
  1 423 (21) 451 (22) 438 (22) 467 (23) 1088 (22) 691 (23) 1779 (22) 2300 (22)




 Angina pectoris 50 (2) 75 (4) 73 (4) 80 (4) 161 (3) 117 (4) 278 (3) 342 (3)
 Myocardial 
infarction
0 0 0 0 0 0 0 1 (< 1)
Cardiovascular risk 
 factorsb, n (%)




112 (6) 117 (6) 138 (7) 166 (8) 308 (6) 225 (7) 533 (7) 681 (7)
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experienced within the first 16 weeks of the trial: 22–30% 
of patients who continued in the trial, and had Week 16 
fibrinogen data, experienced an exacerbation within the 
first 16  weeks; 46% of patients who withdrew from the 
trial on or prior to Week 16, and therefore did not have 
fibrinogen data, experienced an exacerbation within 
this time period. Differences between Week 16 fibrino-
gen levels in patients who received FF/UMEC/VI versus 
FF/VI (1%), FF/UMEC/VI versus UMEC/VI (2%), and 
UMEC/VI versus FF/VI (− 1%) were below the pre-spec-
ified ≤ 15% indicating no evidence of a potential treat-
ment effect on Week 16 fibrinogen (Table 4 in Additional 
File 1). Based on these results Week 16 Fibrinogen was 
considered appropriate to use as baseline measurement.
Efficacy
On‑treatment exacerbation rates
The rates of moderate, moderate/severe, and severe exac-
erbations increased with increasing fibrinogen quartiles 
(Fig.  1). Significant differences (indicated by 95% confi-
dence interval [CI] that did not cross 1) were observed 
between the rates of moderate/severe and severe exacer-
bations for Quartile 4 versus Quartile 1, with rate ratios 
of 1.16 and 1.44, respectively (Fig. 1). Similarly, a signifi-
cant difference was also observed between Quartile 3 and 
Quartile 1, with rate ratios of 1.11 and 1.28, for moder-
ate/severe and severe exacerbations, respectively (Fig. 1). 
For moderate exacerbations, the difference was sig-
nificant only for Quartile 4 versus Quartile 1 (rate ratio 
1.12) (Fig. 1). When analyzed by treatment arm in each 
quartile subgroup, the rate ratio point estimates for mod-
erate, moderate/severe, and severe exacerbations were 
generally in favor of FF/UMEC/VI over each dual therapy 
(Fig. 2).
Exacerbation rates were also higher in patients with 
fibrinogen levels ≥ 3.5  g/L versus < 3.5  g/L, with rate 
ratios of 1.08 for moderate/severe exacerbations and 
1.30 for severe exacerbations (Fig.  3). Analysis by 
treatment group in each fibrinogen threshold sub-
group showed that FF/UMEC/VI reduced the rate of 
moderate, moderate/severe, and severe exacerbation 
versus both FF/VI and UMEC/VI in the low fibrinogen 
subgroup (< 3.5 g/L); no significant between-treatment 
differences were seen in patients with fibrino-
gen ≥ 3.5 g/L (Fig. 4).
Analysis of the rate of on-treatment moderate, mod-
erate/severe, and severe exacerbations by continu-
ous fibrinogen levels showed a general trend for an 
increased rate of exacerbations with increasing fibrino-
gen levels in all treatment arms and for all exacerbation 
types (Fig. 1 in Additional File 1).
Time‑to‑first on‑treatment exacerbation
Kaplan–Meier plots of time-to-first exacerbation 
showed a general trend for increased risk of an on-
treatment moderate, moderate/severe, or severe exac-
erbation with increasing fibrinogen levels (Fig.  5). A 
significantly higher risk of moderate/severe (hazard 
ratio [HR] [95% confidence interval (CI)]: 1.16 [1.04, 
1.28]) and severe (HR: 1.35 [1.09, 1.69]) exacerbations 
was seen between patients in fibrinogen Quartile 4 
compared with Quartile 1.
Analysis of time-to-first exacerbations using the 
3.5  g/L fibrinogen threshold demonstrated a signifi-
cantly higher risk of on-treatment moderate/severe (HR 
[95% CI]: 1.09 [1.00, 1.16]) and severe (HR: 1.27 [1.08, 
1.47]) exacerbations in patients with fibrinogen lev-
els ≥ 3.5  g/L compared with those with levels < 3.5  g/L 
(Fig. 2 in Additional File 1).
All‑cause mortality
Analysis of ACM showed a similar risk of on-/off-treat-
ment mortality in the highest fibrinogen quartile group 
compared with the lower three quartiles (Fig.  6a). 
Similarly, analysis of ACM using the fibrinogen 3.5 g/L 
threshold showed a similar risk of on-/off-treatment 
mortality for fibrinogen levels below and above this 
threshold (Fig. 6b).
Table 2 Exacerbation status up to Week 16 by fibrinogen quartile and withdrawal status
Quartile 1, fibrinogen value < 25th percentile; Quartile 2, fibrinogen value > 25th percentile and < median; Quartile 3, fibrinogen value ≥ median and < 75th percentile; 
Quartile 4, fibrinogen value ≥ 75th percentile
a Patients who discontinued study treatment/withdrew from the study on or prior to Week 16 and did not have a fibrinogen result at Week 16;
b Patients who did not discontinue study treatment/withdraw from the study on or prior to Week 16 but had a missing fibrinogen result at Week 16















Yes, n (%) 452 (22) 476 (24) 509 (25) 609 (30) 547 (46) 271 (25) 2864 (28)
No, n (%) 1565 (78) 1549 (76) 1493 (75) 1441 (70) 648 (54) 795 (75) 7491 (72)
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Safety
Safety data from the IMPACT trial has been previously 
published [3]. In this current analysis, incidence of AESIs 
were similar across all fibrinogen quartiles. The incidence 
of pneumonia was similar (5%) in Quartiles 1, 2 and 3, 
but slightly higher (6%) in Quartile 4. For CV events, the 
overall incidence was similar in each quartile, but Quar-
tile 4 had a slightly higher event rate (162.7) compared 
with Quartiles 1 (139.2), 2 (136.0) and 3 (129.4) (Table 5 
in Additional File 1).
a
Fibrinogen Quartile 2 vs Fibrinogen Quartile 1
Fibrinogen Quartile 3 vs Fibrinogen Quartile 1


















Rate ratio (95% CI)
0.8 1.0 1.2 1.4 1.6 1.8 2.0
b
Fibrinogen Quartile 2 vs Fibrinogen Quartile 1
Fibrinogen Quartile 3 vs Fibrinogen Quartile 1


















Rate ratio (95% CI)
0.8 1.0 1.2 1.4 1.6 1.8 2.0
c
Fibrinogen Quartile 2 vs Fibrinogen Quartile 1
Fibrinogen Quartile 3 vs Fibrinogen Quartile 1


















Rate ratio (95% CI)
0.8 1.0 1.2 1.4 1.6 1.8 2.0
Fig. 1 Rate of on‑treatment exacerbations by quartiles. a Moderate; b moderate/severe; c severe. Rate of exacerbations from Week 16 by Week 16 
fibrinogen quartiles. Quartile 1, fibrinogen value < 25th percentile; Quartile 2, fibrinogen value > 25th percentile and < median; Quartile 3, fibrinogen 
value ≥ median and < 75th percentile; Quartile 4, fibrinogen value ≥ 75th percentile; interaction of treatment with fibrinogen quartile p‑values for 
a–c are 0.494, 0.515 and 0.916 respectively. CI confidence interval
Fig. 2 Rate ratio for on‑treatment exacerbations by quartile. a Moderate; b moderate/severe; c severe. Rate ratio (FF/UMEC/VI vs dual therapies) 
for on‑treatment exacerbations by Week 16 fibrinogen quartile. Quartile 1, fibrinogen value < 25th percentile; Quartile 2, fibrinogen value > 25th 
percentile and < median; Quartile 3, fibrinogen value ≥ median and < 75th percentile; Quartile 4, fibrinogen value ≥ 75th percentile. CI confidence 
interval; FF fluticasone furoate; n number of patients in the analysis in each subgroup; UMEC umeclidinium; VI vilanterol
(See figure on next page.)
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FF/UMEC/VI vs FF/VI (n)
Fibrinogen Quartile 1 (827, 769)
Fibrinogen Quartile 2 (803, 818)
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Discussion
This post hoc analysis of the IMPACT trial was under-
taken to investigate whether plasma fibrinogen could be 
used to stratify a high-risk COPD population and identify 
those most likely to have future events. Our findings indi-
cate an increased rate and risk of exacerbation in patients 
with higher fibrinogen levels, which is seen regardless of 
whether fibrinogen is analyzed by quartiles or by a 3.5 g/L 
threshold. In this analysis, higher (≥ 3.5 g/L) versus lower 
(< 3.5  g/L) fibrinogen levels were associated with an 8% 
increase in exacerbations and a 30% increase in severe 
exacerbations (those leading to hospitalisation or death).
The results from this study support the rationale for 
using fibrinogen levels as a predictive biomarker for clini-
cal trial recruitment as it provides an indicator of patients 
at an increased risk of COPD exacerbations [11]. Patients 
in the highest fibrinogen quartile had a 16% increase in 
the rate of moderate/severe exacerbations compared 
with the lowest quartile. This could be beneficial as an 
enrichment strategy in clinical trials looking at exacer-
bation outcomes, as more exacerbation outputs could 
be gained from fewer patients, and fewer patients would 
be required to demonstrate treatment effects. However, 
it is worth noting that by selecting patients in the high-
est fibrinogen quartile during clinical trial screening, 75% 
of the patient population would be excluded from par-
ticipating. Importantly, findings from this study support 
the utility of fibrinogen as a predictive marker for exac-
erbations in clinical practice; aiding the identification of a 
subgroup of patients with COPD that are at a higher risk 
of experiencing exacerbations and would benefit from 
appropriate treatment to reduce future risk [4]. A gen-
eral trend for increased risk of on-treatment moderate, 
moderate/severe, and severe exacerbations was observed 
with increasing fibrinogen levels for each exacerbation 
type, with a more pronounced change seen for severe 
exacerbations (i.e. those resulting in hospitalization or 
death), than moderate exacerbations. These results are 
in agreement with the studies by Mannino et  al. [11] 
and Kim et  al. [12], which reported that higher fibrino-
gen levels were associated with an increased risk of 
exacerbations in patients with COPD, and the study by 
Celli et  al. [17], which demonstrated an increased risk 
of hospitalized exacerbations at higher fibrinogen levels, 
although no significant association was seen for moder-
ate/severe exacerbations. The analysis of exacerbations 
by continuous fibrinogen levels provides further support 
for increased exacerbation rates in patients with higher 
fibrinogen levels.
The ACM data showed a similar risk of on-/off-treat-
ment mortality when the highest fibrinogen quartile 
group was compared with the lower three quartiles and 
when the < 3.5  g/L and ≥ 3.5  g/L fibrinogen subgroups 
were compared. This differs from results shown in other 
studies that found that higher levels of plasma fibrinogen 
were associated with an increased risk of death [11, 17]. 
These differences could potentially be due to the fact that 
the Week 16 fibrinogen population may not represent all 
patients; furthermore, patients who died prior to Week 
16, and therefore did not have fibrinogen data available, 
were not included in this analysis. Finally, it should be 
noted that this analysis considers a short duration of fol-
low-up (from Week 16 to Week 52), and that there were 
few events, which may have limited power.
The analysis of the rate of exacerbations by treatment 
and fibrinogen quartiles showed that rate ratio point 
estimates were generally in favor of FF/UMEC/VI ver-
sus both dual therapies in all quartile subgroups, with 
the most pronounced effect seen in the second quartile 
(fibrinogen ≥ 2.780 to < 3.280 g/L), and smaller between-
treatment differences generally seen in the two highest 
quartiles. The analysis of exacerbation rates by treatment 
and fibrinogen threshold of 3.5 g/L showed a significant 
benefit of FF/UMEC/VI over FF/VI and UMEC/VI only 
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Fig. 3 Rate of on‑treatment exacerbations by 3.5 g/L threshold. Rate of on‑treatment exacerbations from Week 16 by Week 16 fibrinogen 3.5 g/L 
threshold. CI confidence interval
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patients in the analysis in each subgroup; UMEC umeclidinium; VI vilanterol























168 196 224 25214011284










































































168 196 224 25214011284






































































168 196 224 25214011284


















































Fig. 5 Time‑to‑first on‑treatment exacerbation by quartile. a Moderate; b moderate/severe; c severe. Time‑to‑first on‑treatment exacerbation from 
Week 16 by Week 16 fibrinogen quartile. Interaction of treatment with fibrinogen quartile p‑values for a–c are 0.695, 0.599 and 0.783 respectively: 
Quartile 1: < 2.780 g/L; Quartile 2: ≥ 2.780 g/L; Quartile 3: < 3.830 g/L; Quartile 4: ≥ 3.830 g/L
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in patients with fibrinogen < 3.5 g/L. The explanation for 
this is unclear. Due to the lack of data before Week 16, 
these results should be interpreted with caution as this 
limits inferences that may be made around treatment 
effect; there was a lower rate of treatment discontinua-
tion in patients treated with triple versus dual therapy 
[3], possibly confounding any potential treatment effects. 
Finally, patients with higher fibrinogen levels had more 
exacerbations, and it is possible to speculate that these 
could be biologically different events that did not respond 
as well to ICS.
Fibrinogen is a known risk factor in CV disease, 
and fibrinogen levels have been shown to be higher in 
patients with CV disease than those without [18]. In 
our analyses, the highest fibrinogen quartile had similar 
incidence of CV events compared with the other quar-
tiles, with only a small increase in annual event rate 
(0.16 event per patient-year in the highest quartile vs 
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Fig. 6 All‑cause mortality on and off‑treatment by a fibrinogen quartile; b fibrinogen 3.5 g/L threshold. Quartile 1: < 2.780 g/L; Quartile 
2: ≥ 2.780 g/L; Quartile 3: < 3.830 g/L; Quartile 4: ≥ 3.830 g/L
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were independently adjudicated in the IMPACT trial; 
therefore, the lack of an observable increase in AESIs 
with increasing levels of fibrinogen in our analysis could 
potentially be due to AEs being misclassified by the clini-
cian as respiratory in nature when in fact they were CV 
events because of overlapping clinical symptoms between 
the diseases [19, 20].
Systemic inflammation has been associated with CV 
disease, cancer, and metabolic syndrome as well as 
COPD [9, 21–23]. The relationship between reduced 
fibrinogen and protection from exacerbations [9, 11, 24], 
suggests that there might be a low-grade inflammatory 
condition in the lung or extrapulmonary that predisposes 
patients to exacerbations. It is well known that ICS and 
LABA therapy can reduce exacerbations in patients with 
a low risk of exacerbations [25]. However, the absence of 
an effect of treatment on fibrinogen levels suggests that 
the site of this ongoing inflammatory response may not 
reside in the lung. It should be noted that patients with 
COPD may also suffer from comorbid diseases that could 
drive an increase in fibrinogen levels, such as cardiac fail-
ure or diabetes; therefore, higher fibrinogen levels may 
also be an indicator of a comorbidity [4].
The sample size for the IMPACT trial was large allow-
ing for these subgroup analyses; however, there are limi-
tations that should be considered when interpreting 
these data. Fibrinogen data were only collected at Week 
16. This is supported by previous studies that had shown 
that treatment with oral steroids [16] or ICS/LABA [15] 
did not have an effect on fibrinogen levels. However, it 
is worth noting that the exacerbation incidence within 
the first 16  weeks was higher in patients who withdrew 
from the study compared with those who remained in the 
study. Furthermore, 2261 patients did not have fibrinogen 
data; had data been available for these patients, a differ-
ent result may have been observed. Additionally, survival 
bias may mean that patients included in this analysis are 
not representative of a general patient population with 
COPD. Furthermore, overall data from the IMPACT trial 
indicates there was a clear separation between treatment 
arms for both moderate or severe exacerbations and 
mortality by Week 16, with ACM significantly lower for 
FF-containing therapies, which could have influenced the 
results [3].
Conclusions
In this post hoc analysis of fibrinogen levels in the 
IMPACT trial, higher fibrinogen levels in patients with 
COPD were associated with a higher rate and risk of 
exacerbations. There appeared to be no association 
between fibrinogen levels and risk of death, although 
the lack of data prior to Week 16 and the relatively 
small number of deaths overall limit interpretation 
on risk of death, in addition to the assessment of any 
potential treatment effects. The incidence of AESIs was 
similar between fibrinogen levels, with pneumonia and 
CV events slightly more common at the highest fibrin-
ogen quartile. Overall, our findings confirm the utility 
of fibrinogen as a predictive biomarker of exacerbation 
risk but not for risk of mortality.
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